Corte Madera, CA, United States of America

Michael R Hanley

This inventor holds 26 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Hybrid Polypeptides. Top assignees: Amylin Pharmaceuticals, Inc., Astrazeneca Pharmaceuticals LP, Duo Security, Inc.. Active years: 2004-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael R Hanley. Retrieved from https://idiyas.com/inventor/michael-r-hanley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 

% Patents Active = 61.5


 

Average Co-Inventor Count = 4.8

ph-index = 10

Forward Citations = 301(Granted Patents)


Location History:

  • Corte Madero, CA (US) (2012)
  • Brookline, MA (US) (2013)
  • San Diego, CA (US) (2010 - 2015)
  • Corte Madera, CA (US) (2004 - 2016)
  • Ann Arbor, MI (US) (2017 - 2021)

Company Filing History:


Years Active: 2004-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Endpoint Management
Hybrid Polypeptides
Peptide Treatments
GIP Analog
Amylin Family Peptides
Medication Dispensing
DPP-IV Resistant
Psychiatric Disorders
Chemokine Receptor
Modulators
Adjustable Mechanism
Glucose Lowering Activity
26 patents (USPTO):Explore Patents

Introduction

Michael R. Hanley, based in Corte Madera, CA, is a distinguished inventor with an impressive portfolio of 26 patents. His work has significantly contributed to advancements in computer security and authentication technologies. By focusing on practical solutions for endpoint management, Hanley has carved a unique niche in the tech world.

Latest Patents

Among Hanley's most recent innovations are two notable patents that demonstrate his expertise in mitigating security vulnerabilities. The first, titled "Systems and Methods for Endpoint Management," outlines a comprehensive approach for detecting and managing authentication attempts from endpoint computing devices. It emphasizes the importance of gathering management status data to control access to computer networks based on successful authentication and the status of the endpoint device.

The second patent, "Method for Automatic Possession-Factor Authentication," introduces a system that utilizes implicit authentication data tied to a user's possession factor. This method generates a possession confidence level to determine an appropriate authentication requirement for transactions, ensuring identity verification while enhancing user experience.

Career Highlights

Michael R. Hanley's career encompasses significant roles in reputable companies such as Amylin Pharmaceuticals, Inc., and AstraZeneca Pharmaceuticals LP. His contributions to these organizations have been foundational in driving innovative approaches toward security and authentication.

Collaborations

Throughout his career, Hanley has collaborated with notable professionals in the field, including Christine Marie Mack and David Geoffrey Parkes. These partnerships have enabled him to enhance his projects further and push the boundaries of current security technologies.

Conclusion

In summary, Michael R. Hanley's contributions to the field of endpoint management and authentication reflect a blend of innovative thinking and practical application. As he continues to uncover new solutions, his impact on the tech industry remains substantial, paving the way for secure computing environments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…